References:
  1. Anstey A, Lear JT: Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs . 1998 Jan;9(1):33-47.
  2. Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol . 2004 Sep;2(9):731-43.
  3. Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol. 2013;19:1699-706.
  4. Ladrière M. [Current indications of azathioprine in nephrology].Nephrol Ther . 2013 Feb;9(1):8-12.
  5. Wee JS, Marinaki A, Smith CH. Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity. BMJ. 2011 Mar 25;342:d1417.
  6. Avallone EV, Pica R, Cassieri C, Zippi M, Paoluzi P, Vernia P. Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects. Eur Rev Med Pharmacol Sci. 2014; 18(2): 165–70.
  7. Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, et al. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective. experience. Scand J Gastroenterol. 2017;52:981-7.
  8. Alves da Silva JI;Caetano C;Pedroto I; (n.d.).Azathioprine-induced acute submandibular sialadenitis in a crohn’s disease patient . GE Portuguese journal of gastroenterology. 2020 Aug; 27(5): 361–363.
  9. Vinayak V, Annigeri RG, Patel HA, Mittal S. Adverse affects of drugs on saliva and salivary glands. J Orofac Sci.  2013;5((1)):15–20.
  10. Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for thiopurine therapy for inflammatory bowel diseases – a clinical practice update: commentary. Gastroenterology. 2019 Jan; 156(1): 36–42.
  11. Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, et al.; German IBD Study Group. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases – a prospective study on incidence and severity. J Crohns Colitis. 2016 Jan; 10(1):61–8.
  12. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Jul; 24(2): 331–42.
  13. Krishnamurthy S, Vasudeva SB, Vijayasarathy S. Salivary gland disorders: a comprehensive review. World J Stomatol. 2015;4:56-71.
  14. Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AM, Proctor G, et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017 Mar; 17(1): 1–28.
  15. Vinayak V, Annigeri RG, Patel HA, Mittal S. Adverse affects of drugs on saliva and salivary glands. J Orofac Sci. 2013; 5(1): 15–20.